Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
Go back to Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735| ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) | Delayed: 33.43 -0.43 (1.27%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $33.86 | 52 Week High | $5.17 | |||
| Open | $33.86 | 52 Week Low | $0.94 | |||
| Day High | $34.01 | P/E | N/A | |||
| Day Low | $32.84 | EPS | $0.00 | |||
| Volume | 2,890,542 | |||||
